

# Sharda Cropchem Limited

Tel. : +91 22 66782800  
FAX : +91 22 66782828 / 66782808  
E-mail : office@shardaintl.com  
Regd. Office : Prime Business Park, Dashrathlal Joshi Road, Vile Parle (W),  
Mumbai - 400056, India.  
www.shardacropchem.com

  
ISO 9001: 2015 Reg. No: 702949  
CJN: L51909MH2004PLC145007



**25<sup>th</sup> October, 2024**

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051  <b>Trading Symbol: SHARDACROP</b>	<b>BSE Limited</b> Phiroze Jeejeebhoi Tower, Dalal Street, Mumbai – 400 001  <b>Scrip Code: 538666</b>
--	---

**Subject: Investors / Analyst's Presentation for the Quarter and half year ended 30<sup>th</sup> September, 2024.**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing herewith the presentation to be made to the Investors/Analysts on the Financial Results of the Company for the quarter & half year ended 30<sup>th</sup> September, 2024.

The presentation is also being uploaded on the website of the Company [www.shardacropchem.com](http://www.shardacropchem.com) in accordance with Regulation 46 of the Listing Regulations.

We request you to take the same on record.

Yours Sincerely,

**Jetkin Gudhka**  
**Company Secretary &**  
**Compliance Officer**

**Encl.: As above**



*Sharda Cropchem Limited*

**SECURING HARVESTS, NURTURING FUTURES.**

**Investor Presentation**

October 2024

# SAFE HARBOR

This presentation has been prepared by and is the sole responsibility of **Sharda Cropchem Limited** (the “Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer or recommendation to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment thereof. In particular, this presentation is not intended to be a prospectus or offer document under the applicable laws of any jurisdiction, including India. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. There is no obligation to update, modify or amend this communication or to otherwise notify the recipient if the information, opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

Certain statements contained in this presentation that are not statements of historical fact constitute “forward-looking statements.” You can generally identify forward looking statements by terminology such as “aim”, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “objective”, “goal”, “plan”, “potential”, “project”, “pursue”, “shall”, “should”, “will”, “would”, or other words or phrases of similar import. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or other projections. Important factors that could cause actual results, performance or achievements to differ materially include, among others: (a) our ability to successfully implement our strategy, (b) our growth and expansion plans, (c) changes in regulatory norms applicable to the Company, (d) technological changes, (e) investment income, (f) cash flow projections, and (g) other risks.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes.



**About Sharda Cropchem Limited**



“We are a fast-growing global agrochemicals company with a peer position in the generic crop protection chemicals industry. Our vast and growing library of dossiers and IPRs provide us solid foundations for growth in the global marketplace, especially in Advanced Markets such as Europe, North America and Latin America. It equips us with the ability to operate in a diversified range of formulations and generic active ingredients space globally”

# AGROCHEMICAL FOCUSED COMPANY

Sharda Cropchem is an Intellectual Property (IP) driven company engaged in marketing and distribution of wide range of formulations and generic active ingredients



**Asset Light Business Model** : Efficiently channelizing time and resources for strengthening core competency of identifying generic molecules and registration opportunities which offer scalable growth with limited capital requirements



**Large Pipeline of Registrations\*** : Procured 2,934 registrations. Additionally, it has filed 1,034 applications for registrations globally pending at different stages



**Diversified Sourcing Arrangements** : Enduring relationship with multiple manufacturers and formulators enables to source and supply formulations or generic active ingredients at competitive prices



**Consistently Increasing Global Presence** : With diversified range of product portfolio, Company has grown by expanding business operations in 80+ countries, across Europe, NAFTA, Latin America and ROW



**Widespread Distribution Network** : Presence in the entire agrochemical value chain with 525 third party distributors and 500+ sales force serving the Company's esteemed clientele in 80+ countries



**Company's apt domain knowledge and experience gives substantial competitive advantage for expanding business in existing markets and new geographies**

\*As on 30<sup>th</sup> September 2024

# ASSET LIGHT BUSINESS MODEL

## Overall Agrochemical Value Chain

Sharda's Operating Area



Focus on identification of generic molecules, preparing dossiers, seeking registrations, marketing & distributing formulations through third-party distributors and/or own sales force

Manufacturing of AIs and formulations is outsourced

**Acts as a key differentiator from an innovator company, allowing the Company to save its capital, time and resources on R&D**

**Highly flexible operating model resulting in :**

- Overall cost competitiveness
- Efficient management of fluctuating market demand across various geographies
- Offering wide range of formulations and AIs

# INCREASING GLOBAL PRESENCE WITH A WIDESPREAD DISTRIBUTION



Presence

**80+** countries

across Europe, NAFTA, LATAM & RoW

Global Resource Deployment

**500+**



Distributors

**525+**

CAPEX incurred in H1FY25

**~Rs. 155 Cr.**

Over the years, the Company has built a strong brand franchise within our global markets; we are benefiting through the economies of scale in our portfolio and leveraging value of our supply chain to deliver value to our customers across geographies

In addition to newer markets, the wide global presence has allowed us to find new, specialised sales and local marketing talent.

Successfully adopted a factory-to-farmer approach to become a one-stop solution provider to our global customers



Strengthening and widening the sales force in Europe, USA, Canada, Mexico, Colombia, South Africa, India, and rest of the world, in addition to third party distributors with a goal to enhance its presence in the agrochemical value chain



It enables the Company to penetrate its formulations and generic active ingredients in various countries backed by the third-party distributors and presence of its own sales force



Company has gained a great deal from globalization, including new customers and diverse geocentric revenue streams. Over the years, we have mastered flexibility and adopted innovative ways to grow our business overseas

# The Sharda Advantage

Global Reach

Wide Product Range

Healthy Relationships with Suppliers

Quality with Affordability

Faster Sales Service

One Stop Solution Provider for Crop Care Products

# WAY FORWARD

1

## Forward Integration - Build Sales Force

- ✓ Leverage market presence and execution capabilities
- ✓ Adopt the factory to farmer approach and be a one stop solution provider
- ✓ Strategy on ground in different regions of NAFTA, Europe, LATAM and other key markets in ROW

2

## Expand & Strengthen Distribution Presence

- ✓ Expand geographical reach using existing library of dossiers
- ✓ Two-fold strategy of further penetrating existing markets and entering new markets

3

## Continual Investment in Product Registrations

- ✓ Continue to identify generic molecules going off patent
- ✓ Investing in preparing dossiers and seeking registrations in own name

4


## Focus on Operational Efficiencies

- ✓ Accelerated focus on revenue generating investments
- ✓ Margin improvements
- ✓ Better cost management and eliminate NVAs



# INDUSTRY OUTLOOK & GROWTH DRIVERS

Global crop protection  
(In Billion USD) – CAGR of 4.3%



## INDUSTRY DRIVERS

**A Growing Population:** Global population is set to increase by 1.2 billion by 2030 and 2 billion by 2050, while the middle class will more than double to 4.9 billion by 2030



A growing middle class fuels demand for increased food and protein production, which in turn drives demand for grain to support growth




Fewer arable acres per capita means that products need to continue to maximise farmer yields; arable land is expected to decrease from half an acre per person today to less than one-third of an acre per person by 2050

# Experienced Management



Sharda Cropchem Limited



**Mr. Ramprakash V. Bubna**  
Chairman & Managing Director

- ✓ Holds a Bachelor's Degree of Technology in Chemical Engineering from IIT, Bombay
- ✓ He has over 56 years of experience in chemicals, agrochemicals and related businesses
- ✓ He is responsible for the Company's overall business operations and strategy



**Mr. Ashish Bubna**  
Whole Time Director

- ✓ Holds a Bachelor's Degree in Commerce from the University of Mumbai
- ✓ Over 33 years of experience in marketing of chemicals, agrochemicals and related businesses.
- ✓ Instrumental in strategizing early investment in product registrations and building the library of product dossiers.
- ✓ Responsible for marketing, procurement, registrations and logistics functions of the agrochemical business.



**Mr. Manish Bubna**  
Whole Time Director

- ✓ Holds a Bachelor's Degree in Chemical Engineering from the Department of Chemical Technology, Bombay University.
- ✓ Over 31 years of experience in chemicals, agrochemicals and related businesses
- ✓ Spearheaded the Company's foray into the conveyor belt and general chemicals business
- ✓ Also oversees the information technology, logistics and documentation functions of the Company



**Q2 FY25 Financial Highlights**

# Q2 FY25: SEGMENT WISE HIGHLIGHTS

₹ Cr.

Agrochemical Segment

Non-Agrochemical Segment

TOTAL REVENUES

76%

82%


24%

18%

% of Revenue



100%

100%



# Q2 FY25: PRODUCT WISE HIGHLIGHTS (Agrochemical Segment)

₹ Cr.




# Q2 FY25: REGION WISE BREAKUP (Agrochemical Segment)

₹ Cr.

## Europe

53%


64%



## NAFTA Region


30%

20%



## TOTAL REVENUES


(Agrochemical Segment)



## LATAM Region

11%


9%



## RoW

6%

7%



% of Revenue

On Consolidated Basis

# Q2 FY25: REGION WISE BREAKUP (Non - Agrochemical Segment)

₹ Cr.

## Europe

16%

17%

23

+5%

24

Q2 FY24

Q2 FY25

## NAFTA Region

61%

65%

86

+7%

92

Q2 FY24

Q2 FY25

## TOTAL REVENUES

(Non - Agrochemical Segment)

140

+2%

143

Q2 FY24

Q2 FY25

## LATAM Region

6%

5%

8

-5%

7

Q2 FY24

Q2 FY25

## RoW

17%

13%

24

-18%

19

Q2 FY24

Q2 FY25

% of Revenue


On Consolidated Basis

# Q2 FY25 : FINANCIAL HIGHLIGHTS

₹ Cr.

## Revenues & GP Margin

25.1% 27.6%




Q2 FY24

Q2 FY25

## EBITDA


+125.0%



Q2 FY24

Q2 FY25

## Profit After Tax



Q2 FY24

Q2 FY25

- ✓ Revenue in Q2 FY25 increased by 34% primarily driven by higher volumes and a gradual price increase. We saw volume growth across all regions, with Europe and NAFTA being key contributors
- ✓ Agrochemical volumes grew by 24.6% in Q2 FY25

- ✓ Gross Margins at 27.6% have come back to normalcy and it is expected to improve further in this financial year with prices expected to increase
- ✓ EBITDA for the quarter stood at Rs. 85 crores as compared to Rs. 38 crores in Q2 FY24 with EBITDA Margins improving to 10.9% (up by 440 bps on Y-o-Y basis)
- ✓ PAT for the quarter stood at Rs. 42 crores as compared to a loss of Rs. 28 crores in Q2 FY24



# H1 FY25 Financial Highlights

# H1 FY25: SEGMENT WISE HIGHLIGHTS

₹ Cr.

Agrochemical Segment

Non-Agrochemical Segment

TOTAL REVENUES

75%

84%

25%

16%

% of Revenue



100%

100%



# H1 FY25: PRODUCT WISE HIGHLIGHTS (Agrochemical Segment)

₹ Cr.



# H1 FY25: REGION WISE BREAKUP (Agrochemical Segment)

₹ Cr.

## Europe

52%

58%

477

768

+61%

H1 FY24

H1 FY25

## NAFTA Region

33%

29%

299

375

+26%

H1 FY24

H1 FY25

## TOTAL REVENUES

(Agrochemical Segment)

916

1,313

+43%

H1 FY24

H1 FY25

## LATAM Region

10%

7%

90

98

+9%

H1 FY24

H1 FY25

## RoW

5%

6%

50

72

+45%

H1 FY24

H1 FY25

% of Revenue

On Consolidated Basis

# H1 FY25: REGION WISE BREAKUP (Non - Agrochemical Segment)

₹ Cr.

## Europe

15%

16%

44

40

-9%

H1 FY24

H1 FY25

## NAFTA Region

56%

64%

170

160

-6%

H1 FY24

H1 FY25

## TOTAL REVENUES

(Non - Agrochemical Segment)

303

249

-18%

H1 FY24

H1 FY25

## LATAM Region

6%

8%

19

19

+2%

H1 FY24

H1 FY25

## RoW

23%

12%

69

29

-58%

H1 FY24

H1 FY25


% of Revenue

On Consolidated Basis


# H1 FY25 : FINANCIAL HIGHLIGHTS

₹ Cr.


## Revenues & GP Margin



## EBITDA



## Profit After Tax




- ✓ Revenue in H1 FY25 increased by 28% primarily driven by higher volumes and a gradual price increase. We saw volume growth across all regions, with Europe and NAFTA being key contributors
- ✓ Agrochemical volumes grew by 36.0% in H1 FY25

- ✓ Gross Margins have increased to 28.4% and it is expected to further improve in this financial year with prices expected to increase
- ✓ EBITDA for the half year stood at Rs. 173 crores as compared to -Rs. 28 crores in H1 FY24
- ✓ PAT for the quarter stood at Rs. 70 crores as compared to a loss of Rs. 116 crores in H1 FY24



# STRONG BALANCE SHEET

## Working Capital (in Days)



## Total Equity

**Rs. 2,294 crores**

Rs. 2,237 crores as on Mar'24

## Cash, Bank & Liquid Investments

**Rs. 656 crores**

Rs. 375 crores as on Mar'24



**Annexure**

# Q2 & H1 FY25 FINANCIAL HIGHLIGHTS

₹ Cr.

Particulars	Q2 FY25	Q2 FY24	Y-o-Y	H1 FY25	H1 FY24	Y-o-Y
<b>Revenue from Operations</b>	<b>776.9</b>	<b>580.8</b>	<b>34%</b>	<b>1,562.0</b>	<b>1,218.5</b>	<b>28%</b>
COGS	562.2	435.2		1,118.4	1,017.3	
<b>Gross Profit</b>	<b>214.7</b>	<b>145.5</b>	<b>48%</b>	<b>443.6</b>	<b>201.2</b>	<b>120%</b>
<b>Gross Margin %</b>	<b>27.6%</b>	<b>25.1%</b>		<b>28.4%</b>	<b>16.5%</b>	
Employee Expenses	10.4	9.2		21.5	18.4	
Other Expenses	123.0	101.4		255.4	216.7	
<b>EBITDA*</b>	<b>84.8</b>	<b>37.7</b>	<b>125%</b>	<b>173.2</b>	<b>-28.3</b>	
<b>EBITDA Margin %</b>	<b>10.9%</b>	<b>6.5%</b>		<b>11.1%</b>	<b>-2.3%</b>	
Forex (Gain)/Loss	-19.4	13.7		-11.1	4.2	
Depreciation	69.1	74.0		133.9	144.2	
Other Income	14.4	23.6		33.7	49.6	
<b>EBIT</b>	<b>46.0</b>	<b>-29.2</b>		<b>77.5</b>	<b>-132.7</b>	
<b>EBIT Margin %</b>	<b>5.9%</b>	<b>-5.0%</b>		<b>5.0%</b>	<b>-10.9%</b>	
Finance Cost	0.5	4.6		1.2	5.9	
<b>PBT</b>	<b>45.5</b>	<b>-33.8</b>		<b>76.3</b>	<b>-138.7</b>	
Tax Expense	3.1	-6.3		6.6	-22.4	
<b>PAT</b>	<b>42.4</b>	<b>-27.6</b>		<b>69.7</b>	<b>-116.2</b>	
<b>PAT Margin %</b>	<b>5.5%</b>	<b>-4.7%</b>		<b>4.5%</b>	<b>-9.5%</b>	
<b>Earnings Per Share (EPS) In Rs.</b>	<b>4.70</b>	<b>-3.06</b>		<b>7.72</b>	<b>-12.88</b>	

\* EBITDA is excluding IA & IAUD write-off (Rs. 3.5 cr. in Q2 FY25; Rs. 2.8 cr. in Q2 FY24; Rs.6.5 cr. In H1 FY25; Rs.5.5 cr. in H1 FY24)

# BALANCE SHEET



Sharda Cropchem Limited

₹ Cr.

EQUITY & LIABILITIES	Sep-24	Mar-24
Equity		
Equity share capital	90.2	90.2
Other equity	2,203.5	2,146.9
<b>Equity attributable to equity holders of the Company</b>	<b>2,293.8</b>	<b>2,237.1</b>
Non-controlling interests	0.4	0.4
<b>Total Equity</b>	<b>2,294.1</b>	<b>2,237.5</b>
Non-current liabilities		
Financial liabilities		
Lease liabilities	4.0	7.8
Other financial liabilities	116.3	58.4
Provisions	0.8	1.3
Deferred tax liabilities (net)	152.9	152.8
<b>Total non-current liabilities</b>	<b>273.9</b>	<b>220.3</b>
Current liabilities		
Financial liabilities		
Borrowings	0.7	3.4
Lease liabilities	7.5	7.2
Trade payables		
total outstanding dues of micro enterprises and small enterprises	5.9	6.9
other than micro enterprises and small enterprises	728.0	914.2
Other financial liabilities	406.0	502.5
Other current liabilities	44.9	69.0
Provisions	69.3	76.0
Income Tax Provisions	1.7	1.5
<b>Total current liabilities</b>	<b>1,263.9</b>	<b>1,580.5</b>
<b>Total Equity &amp; Liabilities</b>	<b>3,831.9</b>	<b>4,038.3</b>

ASSETS	Sep-24	Mar-24
Non-current assets		
Property, plant and equipment	3.4	3.8
Right to Use Assets	10.8	14.4
Goodwill	0.0	0.0
Intangible assets	676.8	690.0
Intangible assets under development	292.3	282.9
Financial Assets		
Investments	0.0	0.0
Other Financial Assets	7.6	5.3
Deferred Tax Assets	12.0	10.3
Income tax assets (net)	104.8	72.1
Other non-current assets	15.4	21.7
<b>Total non-current assets</b>	<b>1,123.1</b>	<b>1,100.4</b>
Current assets		
Inventories	949.2	991.6
Financial assets		
Investments	336.0	158.9
Trade receivables	1,021.8	1,498.0
Cash and cash equivalents	196.1	87.3
Bank balance other than cash and cash equivalents	38.4	0.6
Loans	0.0	0.0
Other financial assets	88.3	128.1
Other current assets	79.0	73.4
<b>Total current assets</b>	<b>2,708.8</b>	<b>2,937.9</b>
<b>Total Assets</b>	<b>3,831.9</b>	<b>4,038.3</b>

# CASH FLOW STATEMENT


₹ Cr.

Particulars	H1 FY25	H1 FY24
<b>Profit Before Tax</b>	<b>76.3</b>	<b>-138.7</b>
Adjustments	100.6	124.9
<b>Operating profit before working capital changes</b>	<b>176.9</b>	<b>-13.7</b>
Changes in working capital	321.6	222.0
<b>Cash generated from operations</b>	<b>498.5</b>	<b>208.2</b>
Direct taxes paid (net of refund)	-40.8	-38.5
<b>Net Cash from Operating Activities</b>	<b>457.8</b>	<b>169.8</b>
<b>Net Cash from Investing Activities</b>	<b>-329.3</b>	<b>-146.8</b>
<b>Net Cash from Financing Activities</b>	<b>-34.5</b>	<b>-36.9</b>
Exchange difference arising on conversion (debited) / credited to foreign currency translation reserve	14.0	0.2
<b>Net Change in cash and cash equivalents</b>	<b>108.0</b>	<b>-13.7</b>
Opening Cash Balance	87.3	176.4
Effect of exchange rate changes on cash & cash equivalents held in foreign currencies	0.7	-0.9
<b>Closing Cash Balance</b>	<b>196.1</b>	<b>161.7</b>


# KEY FINANCIAL PERFORMANCE INDICES

₹ Cr.

## Revenue




## EBITDA & EBITDA Margin\*




## Profit After Tax & PAT Margin




## RoCE



## RoE



## Cash, Bank & Liquid Investments^



\* EBITDA is excluding IA & IAUD write-off

^ Total Cash & Cash Equivalents (Includes FDs of Rs. 128 crores clubbed in Non Current Other Financial Assets)

# HISTORICAL PROFIT & LOSS

₹ Cr.

Particulars	FY24	FY23	FY22	FY21	FY20
<b>Revenue from Operations</b>	<b>3,163.0</b>	<b>4,045.2</b>	<b>3,579.8</b>	<b>2,395.6</b>	<b>2,003.0</b>
COGS	2,342.4	2,860.8	2,499.8	1,636.0	1,388.8
<b>Gross Profit</b>	<b>820.6</b>	<b>1,184.4</b>	<b>1,080.0</b>	<b>759.7</b>	<b>614.3</b>
<b>Gross Margin %</b>	<b>25.9%</b>	<b>29.3%</b>	<b>30.2%</b>	<b>31.7%</b>	<b>30.7%</b>
Employee Expenses	42.4	44.8	44.2	37.3	34.9
Other Expenses	494.9	438.9	336.4	305.5	282.4
<b>EBITDA*</b>	<b>318.1</b>	<b>712.6</b>	<b>728.6</b>	<b>455.2</b>	<b>351.7</b>
<b>EBITDA Margin %</b>	<b>10.1%</b>	<b>17.6%</b>	<b>20.4%</b>	<b>19.0%</b>	<b>17.6%</b>
Forex (Gain)/Loss	0.4	57.6	16.5	-19.9	15.1
Depreciation	267.1	248.1	245.3	170.4	137.1
Other Income	59.8	40.3	28.9	45.9	42.1
<b>EBIT</b>	<b>75.5</b>	<b>435.3</b>	<b>466.5</b>	<b>312.2</b>	<b>186.8</b>
<b>EBIT Margin %</b>	<b>2.4%</b>	<b>10.8%</b>	<b>13.0%</b>	<b>13.0%</b>	<b>9.3%</b>
Finance Cost	3.6	4.5	2.2	2.8	1.9
<b>PBT</b>	<b>71.9</b>	<b>430.7</b>	<b>464.2</b>	<b>309.5</b>	<b>184.9</b>
Tax Expense	40.0	88.8	115.0	80.2	20.2
<b>PAT</b>	<b>31.9</b>	<b>342.0</b>	<b>349.3</b>	<b>229.2</b>	<b>164.7</b>
<b>PAT Margin %</b>	<b>1.0%</b>	<b>8.5%</b>	<b>9.8%</b>	<b>9.6%</b>	<b>8.2%</b>
<b>Earnings Per Share (EPS) In Rs.</b>	<b>3.53</b>	<b>37.90</b>	<b>38.71</b>	<b>25.40</b>	<b>18.25</b>

# BALANCE SHEET – EQUITY & LIABILITIES

₹ Cr.

Equities & Liabilities	FY24	FY23	FY22	FY21	FY20
<b>Shareholder's Funds</b>					
Equity and Share Capital	90.2	90.2	90.2	90.2	90.2
Other Equity	2,146.9	2,141.8	1,822.2	1,524.1	1,312.6
Non-controlling Interest	0.4	0.4	0.3	0.3	0.3
<b>Total Equity</b>	<b>2,237.5</b>	<b>2,232.4</b>	<b>1,912.8</b>	<b>1,614.6</b>	<b>1,403.1</b>
<b>Non-Current Liabilities</b>					
Borrowings		-	-	-	0.1
Trade Payables		-	2.4	2.4	2.4
Lease Liabilities	7.8	-	3.5	8.4	-
Other Financial Liabilities	58.4	1.7	1.6	3.2	13.1
Provisions	1.4	2.7	2.3	3.0	2.7
Deferred Tax Liabilities (net)	152.8	143.4	128.9	92.9	69.3
<b>Total Non-Current Liabilities</b>	<b>220.3</b>	<b>147.9</b>	<b>138.6</b>	<b>109.9</b>	<b>87.5</b>
<b>Current Liabilities</b>					
Borrowings	3.4	3.0	38.0	67.8	0.0
Lease Liabilities	7.2	0.0	5.1	4.5	-
Trade Payables	921.2	1,377.6	1,177.6	806.8	686.7
Other Financial Liabilities	502.5	431.4	324.8	149.1	89.7
Other Current Liabilities	69.0	78.1	55.4	58.0	54.4
Current Tax Liabilities	76.0	61.4	4.2	3.2	1.5
Provisions	1.5	19.1	86.7	50.0	24.4
<b>Total Current Liabilities</b>	<b>1,580.5</b>	<b>1,970.6</b>	<b>1,691.8</b>	<b>1,139.4</b>	<b>856.7</b>
<b>Total Equity &amp; Liabilities</b>	<b>4,038.3</b>	<b>4,350.8</b>	<b>3,743.1</b>	<b>2,863.9</b>	<b>2,347.2</b>

# BALANCE SHEET – ASSETS

₹ Cr.

ASSETS	FY24	FY23	FY22	FY21	FY20
<b>Assets</b>					
<b>Non-Current Assets</b>					
Property, Plant and Equipment	3.8	5.0	14.4	20.9	27.8
Right to Use Assets	14.4	0.0	-	-	-
Goodwill	0.0	0.0	0.0	0.4	0.4
Other Intangible assets	690.0	663.0	577.4	523.1	388.1
Intangible assets under development	282.9	203.9	212.2	131.0	161.4
Deferred Tax Assets (net)	10.3	7.9	4.9	6.0	3.9
Non-Current Tax Assets	72.1	72.3	71.6	73.6	72.5
Other financial assets	5.3	120.7	11.2	9.4	11.6
Other Non Current Assets	21.7	19.9	0.0	0.0	0.0
<b>Total Non-Current Assets</b>	<b>1,100.4</b>	<b>1,092.7</b>	<b>891.7</b>	<b>764.5</b>	<b>665.7</b>
<b>Current Assets</b>					
Inventories	991.6	1,134.3	892.8	525.5	382.2
Investments	158.9	31.9	134.4	83.0	115.5
Trade Receivables	1,498.0	1,833.3	1,540.0	1,162.6	988.4
Cash & Cash equivalents	87.3	176.4	56.7	85.6	77.8
Other Bank balances	0.6	0.2	109.3	175.0	75.7
Loans	0.0	0.0	0.5	-	-
Other Financial Assets	128.1	5.5	48.9	28.1	11.3
Other Current Assets	73.4	76.5	68.9	39.6	29.6
<b>Total Current Assets</b>	<b>2,937.9</b>	<b>3,258.2</b>	<b>2,851.5</b>	<b>2,099.3</b>	<b>1,681.5</b>
<b>Total Assets</b>	<b>4,038.3</b>	<b>4,350.8</b>	<b>3,743.1</b>	<b>2,863.9</b>	<b>2,347.2</b>

# CSR ACTIVITIES



Sharda Cropchem Limited

CSR initiatives taken up by the Company are in the areas of Promoting Education, Healthcare, Eradicating Hunger, Empowerment of Women, Animal Welfare, Promotion of Sports and Rural Development Projects

## Promoting Education



## Animal Welfare



## Medical Aid & Relief

### 'मरीजों की देखभाल सच्चा परमार्थ' राज्यपाल कोश्यारी ने युवाओं में बढ़ते नशा पर जताई चिंता

■ प्रसंग, मुंबई : राज्यपाल भगत सिंह कोश्यारी ने मरीजों की देखभाल को सच्चा परमार्थ बताते हुए कहा कि अगर लोग टीबी के मरीजों को गोद लें और देश को टीबी मुक्त बनाने के लिए मरीजों के पोषण आहार के खर्च का वहन करें, तो यह भी दान होगा। इस दौरान उन्होंने युवाओं में तंबाकू के साथ नशे की बढ़ती प्रवृत्ति पर चिंता जताई। वह परमार्थ रत्न पुरस्कार समारोह में बोल रहे थे।

सामाजिक संस्था परमार्थ सेवा समिति की तरफ से राजभवन में आयोजित पुरस्कार और दीपावली स्नेह कार्यक्रम का आयोजन किया गया था। इसमें राज्यपाल के हाथों टाटा मेमोरियल अस्पताल के निदेशक डॉ. राजेंद्र बडवे और उप निदेशक डॉ. शैलेश श्रीखंडे को कैसर के इलाज, सर्जरी और अनुसंधान में उनके उल्लेखनीय कार्य के लिए परमार्थ रत्न पुरस्कार से सम्मानित किया गया। साथ ही, अविनाश साबले को परमार्थ खेल रत्न पुरस्कार से सम्मानित किया गया। समारोह में राजश्री विरला विशिष्ट अतिथि थीं।

शहरीकरण के साथ बढ़ रहा कैसर: डॉ. राजेंद्र बडवे ने कहा कि भारत



में कैसर की दर पश्चिमी देशों की तुलना में कम है, यह संतोष की बात है। लेकिन, देश में बढ़ते शहरीकरण के साथ कैसर की दर बढ़ रही है। अगर 2035 तक तंबाकू की खेती पूरी तरह से बंद कर दी जाए, तो बड़े पैमाने पर कैसर को नियंत्रित किया जा सकता है, क्योंकि कुल कैसर रोगियों में से तंबाकू के सेवन से होने वाले कैसर रोगियों की संख्या 40 प्रतिशत है। संस्था अध्यक्ष मनमोहन गोयनका ने संस्था की ओर से किए जा रहे कार्यों की रूपरेखा

रखी। संस्था के चेयरमैन लक्ष्मीनारायण विद्यानी ने 18 मॉडल कोमोथेरेपी सेंटर टाटा मेमोरियल हॉस्पिटल को बनाकर दान में देने की घोषणा की। इस अवसर पर महिला समिति की अध्यक्ष शारदा रामप्रकाश बूवना, बजरंगलाल तापड़िया, महावीरप्रसाद तापड़िया, ज्योतिप्रसाद तापड़िया, दिलीप पिरामल, रवि लालपुरिया, कैलाश अग्रवाल, रमेश पोद्दार सहित बड़ी संख्या में लोग उपस्थित थे।

**SECURING HARVESTS, NURTURING FUTURES.**

**THANK YOU**

**Company: Sharda Cropchem Limited**



*Sharda Cropchem Limited*

CIN: L51909MH2004PLC145007

**Mr. Shailesh Mehendale – CFO**

[cfo@shardaintl.com](mailto:cfo@shardaintl.com)  
[finance@shardaintl.com](mailto:finance@shardaintl.com)

Tel: +91 22 6678 2800

**Investor Relation Advisors: Strategic Growth Advisors Pvt. Ltd.**

**SGA** Strategic Growth Advisors

CIN: U74140MH2010PTC204285

**Mr. Deven Dhruva**

[deven.dhruva@sgapl.net](mailto:deven.dhruva@sgapl.net)

Tel: +91 98333 73300